Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;102(5):995-1009.
doi: 10.1007/s00277-023-05170-0. Epub 2023 Mar 22.

Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments

Affiliations
Review

Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments

Xiaolei Wei et al. Ann Hematol. 2023 May.

Abstract

Among hematological malignancies, multiple myeloma (MM) represents the leading indication of autologous hematopoietic stem cell transplantation (auto-HCT). Auto-HCT is predominantly performed with peripheral blood stem cells (PBSCs), and the mobilization and collection of PBSCs are essential steps for auto-HCT. Despite the improved success of conventional methods with the incorporation of novel agents for PBSC mobilization in MM, mobilization failure is still a concern. The current review comprehensively summarizes various mobilization strategies for mobilizing PBSCs in MM patients and the evolution of these strategies over time. Moreover, existing evidence substantiates that the mobilization regimen used may be an important determinant of graft content. However, limited data are available on the effects of graft characteristics in patient outcomes other than hematopoietic engraftment. In this review, we discussed the effect of graft characteristics on clinical outcomes, mobilization failure, factors predictive of poor mobilization, and potential mobilization regimens for such patients.

Keywords: Graft characteristics; Mobilization regimen; Multiple myeloma; Stem cell mobilization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–1107. doi: 10.1002/ajh.26590. - DOI - PMC - PubMed
    1. Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9:44. doi: 10.1038/s41408-019-0205-9. - DOI - PMC - PubMed
    1. Parrondo RD, Ailawadhi S, Sher T, et al. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020;16:56–66. doi: 10.1200/JOP.19.00335. - DOI - PubMed
    1. Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–1664. doi: 10.1038/s41409-021-01227-8. - DOI - PMC - PubMed
    1. Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28:31–40. doi: 10.1016/j.blre.2014.01.001. - DOI - PMC - PubMed

MeSH terms

Substances